Jazz Pharma Plc (JAZZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -356,148 | 560,120 | 414,832 | -224,060 | -329,668 |
| Depreciation Amortization | 696,297 | 660,067 | 638,696 | 629,471 | 552,483 |
| Income taxes - deferred | -444,971 | -208,327 | -260,217 | -292,251 | 69,198 |
| Accounts receivable | -106,279 | -21,115 | -51,883 | -90,135 | -92,735 |
| Accounts payable and accrued liabilities | 39,851 | -20,073 | 9,603 | -11,225 | 57,021 |
| Other Working Capital | 18,899 | -76,720 | -204,439 | 9,905 | -47,952 |
| Other Operating Activity | 1,508,124 | 501,956 | 545,415 | 1,250,272 | 570,160 |
| Operating Cash Flow | $1,355,773 | $1,395,908 | $1,092,007 | $1,271,977 | $778,507 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -470,275 | -460,125 | -120,100 | -1,036 | 1,068,181 |
| PPE Investments | -888,638 | -38,070 | -23,962 | -29,046 | -27,641 |
| Net Acquisitions | N/A | N/A | N/A | 53,000 | -6,234,792 |
| Purchase Sale Intangibles | -151,000 | -10,000 | -19,000 | -469,148 | -17,891 |
| Other Investing Activity | -151,000 | -10,000 | -19,000 | -469,148 | -17,891 |
| Investing Cash Flow | $-1,509,913 | $-508,195 | $-163,062 | $-446,230 | $-5,212,143 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 0 | 980,767 | 0 | N/A | 5,191,463 |
| Debt Repayment | -781,000 | -606,000 | -31,000 | -582,014 | -1,320,600 |
| Common Stock Issued | 107,863 | 20,647 | 46,459 | 98,020 | 135,261 |
| Common Stock Repurchased | -125,023 | -311,429 | -269,761 | -54 | 0 |
| Other Financing Activity | -75,220 | -63,469 | -50,952 | -45,443 | -35,602 |
| Financing Cash Flow | $-873,380 | $20,516 | $-305,254 | $-529,491 | $3,970,522 |
| Exchange Rate Effect | 6,555 | -1,675 | 1,137 | -6,222 | -3,207 |
| Beginning Cash Position | 2,412,864 | 1,506,310 | 881,482 | 591,448 | 1,057,769 |
| End Cash Position | 1,391,899 | 2,412,864 | 1,506,310 | 881,482 | 591,448 |
| Net Cash Flow | $-1,020,965 | $906,554 | $624,828 | $290,034 | $-466,321 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,355,773 | 1,395,908 | 1,092,007 | 1,271,977 | 778,507 |
| Capital Expenditure | -916,805 | -38,070 | -23,962 | -29,046 | -27,641 |
| Free Cash Flow | 438,968 | 1,357,838 | 1,068,045 | 1,242,931 | 750,866 |